Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent[1]. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability[1].
Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100 mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice[2].
| Animal Model: | HFD-induced obese male C57BL/6J mice[2] |
| Dosage: | 10, 30, and 100 mg/kg |
| Administration: | Orally administered for 6 weeks |
| Result: | Led to significant dose-dependent body weight reduction by 4.0 g (8.3%), 10 g (21%), and 19 g (40%), respectively, compared to the 48.1 g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100 mg/kg. |
[1]. In Yong Bae, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. Pharmaceutics. 2020 Feb 3;12(2):127.
[2]. Leo Sungwong Choi, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes (Lond). 2021 Jan;45(1):130-142.